Ralliant (NYSE:RAL) Stock Rating Lowered by Zacks Research

Ralliant (NYSE:RAL) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports.

A number of other brokerages also recently issued reports on RAL. Truist Financial reduced their price target on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday. Citigroup decreased their price target on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Morgan Stanley restated an “overweight” rating and issued a $45.00 price target on shares of Ralliant in a research report on Friday. Barclays lowered their target price on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Oppenheimer reduced their price target on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $50.50.

Ralliant Stock Up 4.7%

RAL opened at $43.11 on Monday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The stock’s fifty day simple moving average is $51.26 and its 200 day simple moving average is $46.64. Ralliant has a 1-year low of $37.27 and a 1-year high of $57.02. The stock has a market cap of $4.86 billion and a PE ratio of 33.94.

Ralliant (NYSE:RAL) last announced its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Insider Transactions at Ralliant

In other Ralliant news, Director Kevin E. Bryant bought 1,250 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $39.97 per share, for a total transaction of $49,962.50. Following the purchase, the director directly owned 4,653 shares of the company’s stock, valued at approximately $185,980.41. This represents a 36.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Anelise Angelino Sacks purchased 2,000 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were acquired at an average cost of $41.25 per share, with a total value of $82,500.00. Following the completion of the transaction, the director directly owned 5,403 shares of the company’s stock, valued at $222,873.75. The trade was a 58.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 5,795 shares of company stock valued at $232,405 over the last ninety days.

Institutional Investors Weigh In On Ralliant

Several large investors have recently made changes to their positions in the business. State of Wyoming raised its stake in shares of Ralliant by 445,900.0% during the 4th quarter. State of Wyoming now owns 4,460 shares of the company’s stock worth $227,000 after purchasing an additional 4,459 shares during the period. TD Asset Management Inc raised its position in Ralliant by 9.1% in the fourth quarter. TD Asset Management Inc now owns 232,520 shares of the company’s stock worth $11,838,000 after acquiring an additional 19,340 shares during the period. Bank of New York Mellon Corp boosted its stake in Ralliant by 24.1% in the fourth quarter. Bank of New York Mellon Corp now owns 640,482 shares of the company’s stock valued at $32,607,000 after acquiring an additional 124,516 shares during the last quarter. Natixis Advisors LLC boosted its stake in Ralliant by 19.7% in the fourth quarter. Natixis Advisors LLC now owns 28,312 shares of the company’s stock valued at $1,442,000 after acquiring an additional 4,655 shares during the last quarter. Finally, AXQ Capital LP grew its position in shares of Ralliant by 440.4% during the 4th quarter. AXQ Capital LP now owns 28,100 shares of the company’s stock valued at $1,431,000 after acquiring an additional 22,900 shares during the period.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Senior management and directors have been buying stock recently (Anelise Angelino Sacks 2,000 shares at ~$41.25; SVP Amir Kazmi ~2,545 shares at ~$39.27; Director Kevin Bryant 1,250 shares), which investors often interpret as a sign of management confidence. Read More.
• Positive Sentiment: Ralliant beat Q4 consensus on EPS and revenue and issued Q1/FY2026 guidance (Q1: $0.460–0.520; FY: $2.220–2.420), which supports near‑term earnings expectations. Read More.
• Positive Sentiment: At least one research shop (Vertical Research) upgraded RAL recently, adding to buying interest from some analysts. Read More.
• Neutral Sentiment: Barclays trimmed its price target (from $60 to $52) but maintained an Overweight rating — still implies upside versus current trading but reduces some enthusiasm. Read More.
• Neutral Sentiment: Analysts have been revising targets both up and down after the quarter; consensus remains a moderate buy with an average target near $50.50, reflecting mixed views on near‑term execution versus long‑term potential. Read More.
• Negative Sentiment: The company recorded a $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced prior FY2026 expectations — a material accounting charge that weakens reported equity and triggered analyst re‑ratings. Read More.
• Negative Sentiment: Multiple law firms have launched or publicized investigations into potential securities‑law violations related to the impairment timing and disclosures, increasing regulatory, litigation and reputational risk. Read More. Read More.
• Negative Sentiment: Short interest climbed ~58.7% in January (now ~3.75M shares, ~3.3% of float), which can amplify downside pressure and volatility if negative news continues.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.